Multi-Microcoil Probes for Capillary NMR Detection

用于毛细管 NMR 检测的多微线圈探针

• 批准号: 6798641
• 负责人: TIMOTHY L PECK
• 金额: $ 39.57万
• 依托单位: PROTASIS CORPORATION
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-07-01 至 2009-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6798641
• 关键词: bioengineering /biomedical engineering; biomedical equipment development; high throughput technology; nuclear magnetic resonance spectroscopy

DESCRIPTION (provided by applicant): The overall goal of this SBIR effort is to commercialize a new family of capillary-scale, high-resolution nuclear magnetic resonance (NMR) spectroscopy flowprobes that employ multiple detection cells in a single probe for high throughput. NMR is utilized extensively by the pharmaceutical and biotechnology industries, but remains one of few analytical methods in which parallel data acquisition has not been applied to increase the number of samples that can be simultaneously evaluated. The reasons behind this are the intrinsically related to the hardware involved in data acquisition. Poor throughput (i.e. relatively long time required for NMR analysis) remains a formidable challenge in drug discovery and development. The company submitting this proposal has a demonstrated track record of using SBIR funding to commercialize novel microcoil (capillary-based) NMR probe technologies. This proposal builds upon the speed and throughput advantages that have been achieved in capillary scale NMR to further advance high throughput screening through multi-sample analysis using a single probe. Technical aspects of both probe design and sample management is addressed. The long-term implications of this technological advance to health and health-related companies, particularly pharmaceutical companies, are significant. The ability to coordinate sample entry, sample exit, and NMR data acquisition for multiple samples in a single magnet/spectrometer/probe system pushes the boundaries of NMR and holds potential to dramatically change the way in which NMR is performed in the future.

描述（由申请人提供）： 这项SBIR工作的总体目标是将新的毛细血管尺度，高分辨率核磁共振（NMR）光谱流动性商业化，该光谱流动探针在单个探针中采用多个检测细胞以获得高吞吐量。 NMR被药物和生物技术行业广泛利用，但仍然是少数分析方法之一，其中未应用并行数据采集来增加可以同时评估的样品数量。其背后的原因是与数据采集所涉及的硬件本质上相关。吞吐量较差（即NMR分析所需的相对较长的时间）仍然是药物发现和发育中的巨大挑战。提交此提案的公司具有使用SBIR资金将新颖的Microcoil（基于毛细管）NMR探针技术商业化的记录。该提案建立在毛细管量表NMR中获得的速度和吞吐量优势，以通过使用单个探针通过多样本分析进一步推进高吞吐量筛选。探测设计和样本管理的技术方面均已解决。这种技术进步对健康和健康相关的公司，尤其是制药公司的长期影响非常重要。在单个磁铁/光谱仪/探针系统中为多个样品进行样品输入，样品退出和NMR数据采集的能力，可以按下NMR的边界，并具有显着改变未来NMR的方式。